Quinolones for treatment of nosocomial pneumonia: A meta-analysis

Clinical Infectious Diseases

Volumn 40, Issue SUPPL., 2005, Pages

  Shorr, Andrew F ^a   Susla, Gregory B ^b   Kollef, Marin H ^c,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Voluntary Hosp Assoc of America   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CHOICE; DRUG COMPARISON; DRUG EFFICACY; DRUG QUALITY; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZATION; SAMPLING; SYSTEMATIC REVIEW;

ANTI-INFECTIVE AGENTS; CILASTATIN; CIPROFLOXACIN; CROSS INFECTION; HUMANS; IMIPENEM; META-ANALYSIS; OFLOXACIN; PNEUMONIA, BACTERIAL; QUINOLONES; RANDOMIZED CONTROLLED TRIALS;

EID: 13944261537     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426191     Document Type: Article

References (33)

1. Bruchhaus JD, McEachern R, Campbell GD Jr. Hospital-acquired pneumonia: recent advances in diagnosis, microbiology and treatment. Curr Opin Pulm Med 1998; 4:180-4.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999; 27:887-92.
3. Fagon J-Y, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281-8.
4. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: a consensus statement. Am J Respir Crit Care Med 1996; 153:1711-25.
5. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
6. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-7.
7. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-21.
8. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med 2000; 132:621-30.
9. Mehta R, Niederman MS. Adequate empirical therapy minimizes the impact of diagnostic methods in patients with ventilator-associated pneumonia. Crit Care Med 2000; 28:3092-4.
10. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20:303-16.
11. Cross JT, Campbell GD. Drug-resistant pathogens in community- and hospital-acquired pneumonia. Clin Chest Med 1999; 20:499-506.
12. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-85.
13. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196-200.
14. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-94.
15. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
16. Jadad AR, Cook DJ, Jones A, et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998; 280:278-80.
17. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38:547-57.
18. Saginur R, Garber G, Darling G, et al. Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia. Can J Infect Dis 1997; 8:89-94.
19. Krumpe PE, Cohn S, Garreltes J, et al. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. J Antimicrob Chemother 1999; 43:117-28.
20. Torres A, Bauer TT, Leon-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55:1033-9.
21. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.
22. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003; 45:279-85.
23. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Int J Antimicrob Agents 2002; 19:21-31.
24. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002; 46:586-9.
25. Fabre D, Bressolle F, Gomeni R, et al. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991; 35:2521-5.
26. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21:233S-52S.
27. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32:101-19.
28. Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial therapy. 33rd ed. Hyde Park, VT: Antimicrobial Therapy, 2003.
29. Drusano GL. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J Chemother 2000; 12(Suppl 4):21-6.
30. Dennesen PJW, van der Ven AJAM, Kessels AGH, Ramsay G, Bonten MJM. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-5.
31. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-82.
32. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289:885-8.
33. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.